Edgewise Therapeutics (EWTX) Shares Outstanding (Diluted Average) (2020 - 2026)

Edgewise Therapeutics has disclosed Shares Outstanding (Diluted Average) across 7 years of filings, most recently posting $107.1 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $107.1 million, up 12.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $107.1 million (up 12.6% YoY), and the FY2025 annual result was $102.9 million, up 11.38% from the prior year.
• Shares Outstanding (Diluted Average) came in at $107.1 million for Q1 2026 at Edgewise Therapeutics, up from $102.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $107.1 million in Q1 2026 to a low of $49.5 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $87.6 million (2024), against an average of $78.8 million.
• Peak annual rise in Shares Outstanding (Diluted Average) reached 3076.2% in 2022, while the deepest fall reached 0.66% in 2022.
• Edgewise Therapeutics' Shares Outstanding (Diluted Average) stood at $53.6 million in 2022, then rose by 18.9% to $63.7 million in 2023, then soared by 45.02% to $92.4 million in 2024, then climbed by 11.38% to $102.9 million in 2025, then advanced by 4.07% to $107.1 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $107.1 million (Q1 2026), $102.9 million (Q4 2025), and $105.5 million (Q3 2025), per Business Quant data.